Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record, with a small difference in title or year; 25 of the 26 references it cites were found in a registry or an index.

Gabapentin Reduces Alcohol Consumption and Craving: A Randomized, Double-Blind, Placebo-Controlled Trial

Furieri, Fernando A., Nakamura-Palacios, Ester M. · 2007 · The Journal of Clinical Psychiatry

Abstract

OBJECTIVE: This study examined the efficacy of a 28-day gabapentin treatment in reducing alcohol consumption and craving. METHOD: A randomized, double-blind, placebo-controlled trial was performed in a Brazilian public outpatient drug treatment center, with 60 male alcohol-dependent subjects with a mean age of 44 years and an average of 27 years of alcohol use, who consumed 17 drinks per day (165-170 g/day) over the past 90 days before baseline and had no other significant medical or psychiatric condition. Subjects were recruited between July 8, 2004, and February 24, 2005. Following screening, 60 subjects were selected and received diazepam and vitamins as treatment for acute withdrawal for at least 7 days. After the detoxification treatment, 30 subjects were randomly assigned to receive gabapentin (300 mg twice daily) for 4 weeks, and 30 subjects, with similar baseline characteristics, were randomly assigned to receive matching placebo tablets for the same period. RESULTS: After 28 days of treatment, the gabapentin group showed a significant reduction in both number of drinks per day and mean percentage of heavy drinking days (p = .02 for both), and an increase in the percentage of days of abstinence (p = .008), compared to the placebo group. Additionally, some improvement in obsessive-compulsive symptoms was noted in both groups after the treatment, but it resulted in a more pronounced decrease in automaticity of drinking and aspects of craving in the gabapentin group than in the placebo group. CONCLUSION: Gabapentin reduces alcohol consumption and craving, which may help patients to maintain abstinence. These results, together with the virtual absence of side effects and a favorable safety profile, support gabapentin as a potential drug for the treatment of alcohol withdrawal and dependence.

Overview

Integrity signals

Registry

Crossref · 10.4088/jcp.v68n1108

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 26 references

Cited by

See all 144

Metadata

Authors
Furieri, F. A., & Nakamura-Palacios, E. M.
Affiliations
Prefeitura Municipal de Vitória (BR)
Venue
The Journal of Clinical Psychiatry
Published
2007-11-15
Volume
68
Issue
11
Pages
1691-1700
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2075663070
Cited by
144
References
26
Citations by year
2026: 3 · 2025: 5 · 2024: 6 · 2023: 7 · 2022: 9 · 2021: 4 · 2020: 6 · 2019: 8 · 2018: 13 · 2017: 8 · 2016: 6 · 2015: 13 · 2014: 11 · 2013: 9 · 2012: 12
FWCI
3.90
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Clinical Neurology › Alcoholism and Thiamine Deficiency
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords
gabapentin, alcoholism, alcohol craving, alcohol consumption, alcohol withdrawal, alcohol abstinence, heavy drinking days, obsessive-compulsive symptoms
MeSH terms
Gabapentin, Adolescent, Adult, Aged, Alcohol Deterrents, Ethanol, Alcoholism, Ambulatory Care, Amines, Blood-Brain Barrier, Brazil, Cyclohexanecarboxylic Acids, Double-Blind Method, Drug Administration Schedule, Female, gamma-Aminobutyric Acid, Humans, Male, Middle Aged, Obsessive-Compulsive Disorder, Severity of Illness Index, Substance Withdrawal Syndrome, Temperance, Incidence, Prevalence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gabapentin Reduces Alcohol Consumption and Craving: A Randomized, Double-Blind, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.4088/jcp.v68n1108
The paper
Furieri, F. A., & Nakamura-Palacios, E. M. (2007). Gabapentin Reduces Alcohol Consumption and Craving: A Randomized, Double-Blind, Placebo-Controlled Trial. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v68n1108

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.